medical decision support medical decision support
Sign In

Modified Hepatoma Arterial Embolization (mHAP) Score of Pinato et al for Predicting Survival for a Patient with Hepatocellular Carcinoma

Description

Pinato et al analyzed components of the hepatoma arterial embolization (HAP) score for their ability to predict overall survival for a patient with hepatocellular carcinoma. A modified HAP (mHAP) can help to identify patients who may not benefit from transarterial chemoembolization (TACE). The authors are from multiple institutions in England, Japan, Italy and Korea.


Patient selection: hepatocellular carcinoma, candidate for TACE

 

Difference from original HAP score: removal of serum total bilirubin (area under the ROC curve for bilirubin 0.53)

 

Parameters:

(1) serum albumin in g/L

(2) serum AFP in ng/mL

(3) diamteter of the dominant tumor in cm

 

Parameter

Finding

Points

serum albumin

< 36 g/L

1

 

>= 36 g/L

0

serum AFP

<= 400 ng/mL

0

 

> 400 ng/mL

1

diameter

<= 7 cm

0

 

> 7 cm

1

 

modified hepatoma arterial-embolisation prognostic (mHAP score) =

= SUM(points for all 3 parameters)

 

Interpretation:

• minimum score: 0

• maximum score: 3

• The higher the score the worse the median overall survival.

 

Score

Prognostic Group

Median Overall Survival

0

A

104 months

1

B

47 months

2

C

8 months

3

D

3.8 months

 


To read more or access our algorithms and calculators, please log in or register.

Specialty